拉坦前列素治疗葡萄酒色斑相关的儿童青光眼。
Latanoprost in port wine stain related paediatric glaucoma.
作者信息
Ong T, Chia A, Nischal K K
机构信息
Department of Ophthalmology, Great Ormond Street Hospital for Children, London, UK.
出版信息
Br J Ophthalmol. 2003 Sep;87(9):1091-3. doi: 10.1136/bjo.87.9.1091.
AIM
To evaluate the efficacy of latanoprost (Xalatan) as adjunctive therapy in port wine stain related paediatric glaucoma.
METHODS
A retrospective non-randomised study. Patients with previous surgical intervention and medical treatment were included. Measurements were recorded from clinic and/or examination under anaesthetic (EUA) visits. A successful outcome was considered to be patients who required no further intervention following initiation of latanoprost, with stable glaucoma factors as well as drop in intraocular pressure.
RESULTS
14 patients and 17 eyes were reviewed in total. The mean age of glaucoma diagnosis was 2.59 years (0.1-5.25 years) and of commencing latanoprost was 6.8 years (1.40-12.90 years). Percentage success at 1 month, 3 months, 6 months, and 1 year was 70.6%, 64.7%, 58.9%, and 47.1%, respectively, of eyes treated which translated to 71.4%, 64.2%, 57.1%, and 50% respectively of patients treated.
CONCLUSIONS
A trial of latanoprost as adjunctive therapy in patients with port wine stain related glaucoma may temporise the need for surgery; with 50% of patients being controlled at 1 year follow up. Lack of efficacy was detected as early as 1 month following commencement of treatment.
目的
评估拉坦前列素（适利达）作为辅助治疗在葡萄酒色斑相关小儿青光眼治疗中的疗效。
方法
一项回顾性非随机研究。纳入曾接受手术干预和药物治疗的患者。测量数据记录于门诊就诊和/或麻醉下检查（EUA）时。成功的结果定义为开始使用拉坦前列素后无需进一步干预、青光眼相关因素稳定且眼压降低的患者。
结果
共对14例患者的17只眼进行了评估。青光眼诊断的平均年龄为2.59岁（0.1 - 5.25岁），开始使用拉坦前列素的平均年龄为6.8岁（1.40 - 12.90岁）。接受治疗的眼在1个月、3个月、6个月和1年时的成功率分别为70.6%、64.7%、58.9%和47.1%，换算为接受治疗的患者成功率分别为71.4%、64.2%、57.1%和50%。
结论
在葡萄酒色斑相关青光眼患者中试用拉坦前列素作为辅助治疗可能会推迟手术需求；在1年随访时有50%的患者病情得到控制。在开始治疗后1个月就检测到疗效不佳。
Zotero 插件